Trial Profile
Delirium prevention and prediction,Part 2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2020
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Delirium
- Focus Therapeutic Use
- 07 Aug 2017 New trial record
- 01 Aug 2017 Primary endpoint (Incidence of delirium as determined by the DSM-5.) has been met as per the results published in the Journal of Clinical Psychiatry.
- 01 Aug 2017 Results published in the Journal of Clinical Psychiatry